Beam Therapeutics Inc. — Director's Dealing 2023

Mar 28, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2023-03-16

Reporting Person: Simon Amy (Chief Medical Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	65129	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$80.04	2031-03-31	Common Stock (79500)		Direct
Stock Option (Right to Buy)	$69.21	2032-01-31	Common Stock (30000)		Direct
Stock Option (Right to Buy)	$38.71	2032-06-30	Common Stock (10000)		Direct
Stock Option (Right to Buy)	$43.45	2033-01-31	Common Stock (40000)		Direct

Footnotes

F1: Includes 44,813, 15,000 and 5,000 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, March 31, 2022 and June 30, 2022 respectively.

F2: Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The March 31, 2021 RSUs grant was originally for 59,750 RSUs of which 14,937 RSUs have already vested.

F3: The option vests as to 25% on the first anniversary of the vesting commencement date, March 31, 2022, and at a rate of 2.78% each month thereafter until the option is fully vested.

F4: The option vests at a rate of 2.08% each month after January 31, 2022 until the option is fully vested.

F5: The option vests at a rate of 2.08% each month after June 30, 2022 until the option is fully vested.

F6: The option vests at a rate of 2.08% each month after January 31, 2022 until the option is fully vested.